Elshamaa, M., Fata, M., Swaify, G., El-S. Hegab, S., Tayel, H. (2021). SENTINEL LYMPH NODE BIOPSY AS A PROGNOSTIC TOOL IN EARLY ORAL CANCER USING METHYLENE BLUE DYE. Alexandria Dental Journal, 46(Issue 2), 13-19. doi: 10.21608/adjalexu.2020.88453
Mohamed M. Elshamaa; Mohamed M. Fata; Gamal A. Swaify; Sherif El-S. Hegab; Hanan Y. Tayel. "SENTINEL LYMPH NODE BIOPSY AS A PROGNOSTIC TOOL IN EARLY ORAL CANCER USING METHYLENE BLUE DYE". Alexandria Dental Journal, 46, Issue 2, 2021, 13-19. doi: 10.21608/adjalexu.2020.88453
Elshamaa, M., Fata, M., Swaify, G., El-S. Hegab, S., Tayel, H. (2021). 'SENTINEL LYMPH NODE BIOPSY AS A PROGNOSTIC TOOL IN EARLY ORAL CANCER USING METHYLENE BLUE DYE', Alexandria Dental Journal, 46(Issue 2), pp. 13-19. doi: 10.21608/adjalexu.2020.88453
Elshamaa, M., Fata, M., Swaify, G., El-S. Hegab, S., Tayel, H. SENTINEL LYMPH NODE BIOPSY AS A PROGNOSTIC TOOL IN EARLY ORAL CANCER USING METHYLENE BLUE DYE. Alexandria Dental Journal, 2021; 46(Issue 2): 13-19. doi: 10.21608/adjalexu.2020.88453
SENTINEL LYMPH NODE BIOPSY AS A PROGNOSTIC TOOL IN EARLY ORAL CANCER USING METHYLENE BLUE DYE
1Assistant lecturer at Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Beni Suef, University, Beni Suef, Egypt.
2Professor of Maxillofacial and Plastic Surgery Faculty of Dentistry, Alexandria University, Alexandria, Egypt.
3Professor of Radiodiagnosis and Interventional Radiology Faculty of Medicine, Alexandria University, Alexandria, Egypt.
4Professor of Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Abstract
Introduction: Limited availability of lymphoscintigraphy facilities in Egypt and developing countries requires exploration of alternative methods of SLN detection. Sentinel Lymph Node (SLN) biopsy using a combination of radioisotopes and methylene blue dyes (MBD) have a good accuracy rate in predicting subclinical neck nodal metastases in head and neck cancers. Objectives: Evaluation of the effectiveness of SLN using MBD alone and frozen section of early oral cancer with N0 neck patients in the identification of occult neck micrometastasis and confirmation of the role of SLN in post-surgical follow up. Materials and methods: 12 Patients with cN0 early (T1, T2) oral squamous cell cancers underwent SLN biopsy using peri tumoural MBD injection. Stained SLN nodes were sent for frozen section analyses. Patients had microscopic metastases in SLN underwent modified radical neck dissections and the rest underwent selective neck dissections. Paraffin sections were performed in all cases and immune-histochemistry (IHC) studies were performed on negative lymph nodes. Results: Three cases (25%) SLN couldn't be detected, while nine cases (75%) the blue sentinel lymph node could be identified. Preoperative ultrasound examination of only two cases were not similar to the intraoperative frozen histopathology which reveals the presence of micrometastasis, therefore functional neck dissection was indicated in these two cases and all the frozen sections histopathology were similar to the postoperative paraffin sections. Considering HPE on paraffin fixed blocks as the gold standard, FS had a sensitivity, specificity, and NPV of 95.8 %. IHC with cytokeratin increased the sensitivity (100 %) and NPV (100 %) of histopathology at the loss of specificity (87.5 %) and PPV (62.5 %). Conclusion: SLN biopsy is useful and reliable for patients with early oral cancer that can benefit from reducing unnecessary functional and esthetic complications for N0 patients by reducing the incidence or extent of neck dissection.
2. Samant S. Sentinel node biopsy as an alternative to elective neck dissection for staging of early oral carcinoma. Head Neck. 2014; 36:241-6.
3. Silverman DA, El-Hajj M, Strome S, Esclamado RM. Prevalence of nodal metastases in the submuscular recess (level IIb) during selective neck dissection. Arch Otolaryngol - Head Neck Surg. 2003; 129:724-8.
4. Ambrosch P, Brinck U. Detection of nodal micrometastases in head and neek cancer by serial sectioning and immunostaining. Oncology. 1996; 10:1221-6.
5. Melkane AE, Mamelle G, Wycisk G, Temam S, Janot F, Casiraghi O, et al. Sentinel node biopsy in early oral squamous cell carcinomas: A 10-year experience. Laryngoscope. 2012; 122:1782-8.
6. Dias FL, Kligerman J, Matos De Sá G, Arcuri RA, Freitas EQ, Farias T, et al. Elective neck dissection versus observation in stage I squamous cell carcinomas of the tongue and floor of the mouth. Otolaryngol - Head Neck Surg. 2001; 125:23-9.
7. Suresh, T. N., Harendra Kumar, M. L., Thomas, A. K., & Azeem, M. (2013). Study of sentinel lymph node in oral Squamous cell carcinoma. Journal of Biomedical Science. 2013; 3:146-9.
8. Kurita H, Koike T, Narikawa JN, Sakai H, Nakatsuka A, Uehara S, et al. Clinical predictors for contralateral neck lymph node metastasis from unilateral squamous cell carcinoma in the oral cavity. Oral Oncol. 2004; 40:898-903.
9. Kovács AF, Landes CA, Hamscho N, Risse JH, Berner U, Menzel C. Sentinel node biopsy as staging tool in a multimodality treatment approach to cancer of the oral cavity and the oropharynx. Otolaryngol - Head Neck Surg. 2005; 132:570-6
10. Stoeckli SJ, Pfaltz M, Ross GL, Steinert HC, MacDonald DG, Wittekind C, et al. The Second International Conference on Sentinel Node Biopsy in Mucosal Head and Neck Cancer. In: Annals of Surgical Oncology. 2005; 12:919-24.
11. Vorburger MS, Broglie MA, Soltermann A, Haerle SK, Haile SR, Huber GF, et al. Validity of frozen section in sentinel lymph node biopsy for the staging in oral and oropharyngeal squamous cell carcinoma. J Surg Oncol. 2012; 106:816-9.
12. Chone CT, Aniteli MB, Magalhães RS, Freitas LL, Altemani A, Ramos CD, et al. Impact of immunohistochemistry in sentinel lymph node biopsy in head and neck cancer. Eur Arch OtoRhino-Laryngology. 2013; 270:313-7.
13. Hwang JM, Fu KK, Phillips TL. Results and prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1998; 41:1099-111.
14. Lubin JH, Purdue M, Kelsey K, Zhang ZF, Winn D, Wei Q, et al. Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: A pooled analysis of case-control studies. Am J Epidemiol. 2009; 170:937-47.
15. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Critical Reviews in Oncology/Hematology. 2010; 74:134-48.
16. Saloura V, Langerman A, Rudra S, Chin R, Cohen EEW. Multidisciplinary Care of the Patient with Head and Neck Cancer. Surgical Oncology Clinics of North America. 2013; 22:179- 215.
17. Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, et al. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, ± docetaxel for larynx preservation. J Natl Cancer Inst. 2016; 108:djv368.
18. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013; 31:845-852.
19. Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, Rich JT, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: A United States multicenter study. Head Neck. 2011; 33:1683-94.
20. Bossi P, Alfieri S. The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer. Current Treatment Options in Oncology. 2016; 17:53.
21. Tsai WC, Kung PT, Wang ST, Huang KH, Liu SA. Beneficial impact of multidisciplinary team management on the survival in different stages of oral cavity cancer patients: Results of a nationwide cohort study in Taiwan. Oral Oncol. 2015; 51:105-11.
22. Bergamini C, Locati L, Bossi P, Granata R, Alfieri S, Resteghini C, et al. Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? Oral Oncol. 2016; 54:54-7.
23. Alfieri S, Orlandi E, Bossi P. The Case Volume Issue in Head and Neck Oncology. Current Treatment Options in Oncology. 2017; 18:65.
24. Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. Lancet Oncol. 2017; 18:1022-39.
25. Van Agthoven M, Van Ineveld BM, De Boer MF, Leemans CR, Knegt PP, Snow GB, et al. The costs of head and neck oncology: Primary tumours, recurrent tumours and long-term followup. Eur J Cancer. 2001; 37:2204-11.
26. Morselli P, Zollino I, Pinto V, Brunelli G, Carinci F. Clinical prognostic factors in stage I head and neck squamous cell carcinoma. J Craniofac Surg. 2008; 19:740-3.
27. Silver CE, Croft CB. Elective dissection of the neck. Surg Gynecol Obstet. 1979; 149:65-8.
28. Gourin CG, Johnson JT. A contemporary review of indications for primary surgical care of patients with squamous cell carcinoma of the head and neck. Laryngoscope. 2009; 119:2124-34.
29. Sowder JC, Cannon RB, Buchmann LO, Hunt JP, Hitchcock Y, Lloyd S, et al. Treatmentrelated determinants of survival in early-stage (T1–2N0M0) oral cavity cancer: A populationbased study. Head Neck. 2017; 39:876-80.
30. Eskander A, Monteiro E, Irish J, Gullane P, Gilbert R, De Almeida J, et al. Adherence to guideline-recommended process measures for squamous cell carcinoma of the head and neck in Ontario: Impact of surgeon and hospital volume. Head Neck. 2016; 38:1987-92.
31. Tsai CJ, Zheng J, Zhang Z, Riaz N, Baxi SS, Wong RJ, et al. Association of number of dissected lymph nodes with survival in clinically node-negative oral cavity squamous cell carcinoma patients undergoing primary surgery: A population-based analysis. JAMA Otolaryngol - Head Neck Surg. 2017; 143:1049-52.
View on SCiNiTO
Top